1606 Corp. Files 8-K Report
Ticker: CBDW · Form: 8-K · Filed: Nov 12, 2024 · CIK: 1877461
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
1606 CORP. FILED AN 8-K. CHECK FOR UPDATES.
AI Summary
On November 12, 2024, 1606 Corp. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.
Why It Matters
This filing indicates that 1606 Corp. is meeting its regulatory disclosure requirements with the SEC. Investors can review the filed documents for updates on the company's financial status and any material events.
Risk Assessment
Risk Level: low — The filing is a routine regulatory disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- 1606 Corp. (company) — Registrant
- November 12, 2024 (date) — Date of earliest event reported
- 0001877461 (company) — Central Index Key
- 7372 (company) — Standard Industrial Classification
- NV (company) — State of Incorporation
- 1231 (company) — Fiscal Year End
- 000-56467 (company) — SEC File Number
- 86-1497346 (company) — IRS Employer Identification Number
- 2425 E. Camelback Rd Suite 150 Phoenix , AZ 85016 (company) — Principal executive offices address
- 602-481-1544 (company) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to provide Regulation FD disclosures and to report financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 12, 2024.
What is the company's state of incorporation?
The company, 1606 Corp., is incorporated in Nevada (NV).
What is the company's fiscal year end?
The company's fiscal year ends on December 31 (1231).
What is the principal executive office address of 1606 Corp.?
The principal executive office address of 1606 Corp. is 2425 E. Camelback Rd Suite 150 Phoenix, AZ 85016.
Filing Stats: 663 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2024-11-12 08:00:21
Filing Documents
- cbdw_8k.htm (8-K) — 25KB
- cbdw_ex991.htm (EX-99.1) — 11KB
- 0001477932-24-007007.txt ( ) — 155KB
- cbdw-20241112.xsd (EX-101.SCH) — 6KB
- cbdw-20241112_lab.xml (EX-101.LAB) — 13KB
- cbdw-20241112_cal.xml (EX-101.CAL) — 1KB
- cbdw-20241112_pre.xml (EX-101.PRE) — 8KB
- cbdw-20241112_def.xml (EX-101.DEF) — 2KB
- cbdw_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 12, 2024, 1606 Corp., a Nevada corporation (the " Company "), filed a press release which announced the completion of a merger agreement by Adnexus Biotechnologies Inc. (a company with whom the Company has a letter of intent to acquire a 5% equity stake) to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. The furnishing of the press release is not an admission as to the materiality of any information therein. The information contained in the press release is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the U.S. Securities and Exchange Commission (the " SEC ") and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. The information in this Item 7.01 of this Current Report on Form 8-K and the press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated November 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 1606 Corp. Date: November 12, 2024 By: /s/ Austen Lambrecht Austen Lambrecht, Chief Executive Officer 3